Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Medulloblastoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Pipeline Review, H2 2016, provides an overview of the Medulloblastoma (Oncology) pipeline landscape. Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 3 and 12 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively. Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Medulloblastoma Overview 8 Therapeutics Development 9 Pipeline Products for Medulloblastoma - Overview 9 Pipeline Products for Medulloblastoma - Comparative Analysis 10 Medulloblastoma - Therapeutics under Development by Companies 11 Medulloblastoma - Therapeutics under Investigation by Universities/Institutes 12 Medulloblastoma - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Medulloblastoma - Products under Development by Companies 15 Medulloblastoma - Products under Investigation by Universities/Institutes 16 Medulloblastoma - Companies Involved in Therapeutics Development 17 Bayer AG 17 DelMar Pharmaceuticals Inc 18 Ignyta Inc 19 IMPACT Therapeutics Inc 20 Lipocure Ltd 21 MacroGenics Inc 22 NewLink Genetics Corp 23 Novogen Ltd 24 Progenics Pharmaceuticals Inc 25 Stemline Therapeutics Inc 26 ThromboGenics NV 27 VBI Vaccines Inc 28 Vyriad Inc 29 Medulloblastoma - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Combination Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 (topotecan hydrochloride + vincristine sulfate) - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 dianhydrogalactitol - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Edotreotide Labeled Yttrium 90 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 IMP-5471 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 indoximod - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 irinotecan hydrochloride + TBio-02 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 nifurtimox - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 nifurtimox SR - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Oncolytic Virus to Target CD46 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 p28 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 pyrvinium pamoate - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 SL-301 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 taladegib - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 THR-317 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Trilexium - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 VBI-1901 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Vimo-101 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 VMY-1103 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Medulloblastoma - Dormant Projects 86 Medulloblastoma - Product Development Milestones 87 Featured News & Press Releases 87 Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting 87 Oct 13, 2016: DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations 87 Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 88 Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 89 Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 89 Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083 90 Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant 91 Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors 91 Appendix 94 Methodology 94 Coverage 94 Secondary Research 94 Primary Research 94 Expert Panel Validation 94 Contact Us 94 Disclaimer 95
List of Tables
Number of Products under Development for Medulloblastoma, H2 2016 9 Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Medulloblastoma - Pipeline by Bayer AG, H2 2016 17 Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H2 2016 18 Medulloblastoma - Pipeline by Ignyta Inc, H2 2016 19 Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H2 2016 20 Medulloblastoma - Pipeline by Lipocure Ltd, H2 2016 21 Medulloblastoma - Pipeline by MacroGenics Inc, H2 2016 22 Medulloblastoma - Pipeline by NewLink Genetics Corp, H2 2016 23 Medulloblastoma - Pipeline by Novogen Ltd, H2 2016 24 Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 25 Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H2 2016 26 Medulloblastoma - Pipeline by ThromboGenics NV, H2 2016 27 Medulloblastoma - Pipeline by VBI Vaccines Inc, H2 2016 28 Medulloblastoma - Pipeline by Vyriad Inc, H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Assessment by Combination Products, H2 2016 31 Number of Products by Stage and Target, H2 2016 33 Number of Products by Stage and Mechanism of Action, H2 2016 35 Number of Products by Stage and Route of Administration, H2 2016 37 Number of Products by Stage and Molecule Type, H2 2016 39 Medulloblastoma - Dormant Projects, H2 2016 86
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
